摘要
目的研究肝硬化患者肠球菌感染的现状及药敏特点,以加强对肝硬化肠球菌感染的认识,指导用药。方法留取标本进行细菌培养、鉴定及药敏试验。结果所有纳入研究范围的肝硬化患者共检出肠球菌112株,其中粪肠球菌89株,占79.5%,比例最高,屎肠球菌占14.3%,居第2位。腹水中检出肠球菌64株,占57.1%,其次为痰和尿液,分别为38.1%和14.4%。肠球菌对红霉素、奈替米星的耐药率超过80%,对青霉素G、氨苄西林、呋喃妥因的敏感率超过70%,对左氧氟沙星的敏感率为58.9%,对头孢唑啉、头孢派酮的敏感率分别只有25.0%和33.0%,检出高耐氨基糖苷类肠球菌(HLAR)58株,占51.8%,未检出耐万古霉素和替考拉宁肠球菌,但检出万古霉素中介肠球菌4株,占3.6%。结论肠球菌是肝硬化患者医院感染的重要致病菌,尤以粪肠球菌和屎肠球菌为主,屎肠球菌的耐药率高于粪肠球菌,万古霉素和替考拉宁是治疗肠球菌感染的首选药物。
Objective To study state of Enterococcus infection and monitor the drug resistance in hepatic cirrhosis in vitro. Methods The Enterococcus was cultured by Bact/Alert 120 and identifyied by VITEK-AMS60. Then it＇s drug sensitiveity was tested by K-B method and E-test. Results 112 strains of Enterococcus were isolated from all the patients, among which the most organism was Enterococcusfacialis （9.5%） ,the secondd was E.faecium （ 14.3% ）. 57.1% of Enterococcus was isolated from ascites samples. The resistance rate of Enterococcus to Erythrocin and Netilmicin were over 80%, but the susceptibihty rate to Penicillin, Ampicillin and Nitrofurantoin were over 70% ; to Levofloxacin, Cefazolin, Cefoperazone were 58.9% ,25.0% and 33.0% ,respectively. In all isolated strains,58 strains were high level aminoglycoside- resistant （HLAR）. No vancomycin-resistant and teicoplanin-resistant Enterococcus were isolated,but 4 strains of Enterococ- cus were moderately sensitive to Vancomycin. Conclusions Enterococcus was an important pathogenic bacterium for nosocomial infections in hepatic cirrhosis. Specially, Enterococcusfacialis and E.faecium were the most predominant. The resistance rate of E.faecium was higher than that of Enterococcus facialis. Vancomyein and Teicoplanin were the choice drug in treating Enterococcus infection complicating hepatic cirrhosis.
出处
《中国微生态学杂志》
CAS
CSCD
2007年第6期548-549,554,共3页
Chinese Journal of Microecology
关键词
肠球菌
院内感染
耐药性
肝硬化
Enterococcus
Nosocomial infection
Resistance
Hepatic cirrhosis
